Stifel Financial Corp lessened its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 23.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 161,149 shares of the company’s stock after selling 48,712 shares during the period. Stifel Financial Corp owned 0.33% of LivaNova worth $10,965,000 as of its most recent SEC filing.
Other hedge funds also recently made changes to their positions in the company. PNC Financial Services Group Inc. grew its holdings in LivaNova by 9.8% during the second quarter. PNC Financial Services Group Inc. now owns 1,707 shares of the company’s stock valued at $105,000 after purchasing an additional 153 shares during the last quarter. Riverhead Capital Management LLC grew its stake in shares of LivaNova by 76.3% in the second quarter. Riverhead Capital Management LLC now owns 1,763 shares of the company’s stock worth $108,000 after acquiring an additional 763 shares during the last quarter. Teacher Retirement System of Texas acquired a new stake in shares of LivaNova in the second quarter worth $204,000. Martingale Asset Management L P acquired a new stake in shares of LivaNova in the second quarter worth $221,000. Finally, Bessemer Group Inc. acquired a new stake in shares of LivaNova in the second quarter worth $220,000. Institutional investors own 86.07% of the company’s stock.
Several equities research analysts have recently issued reports on LIVN shares. WBB Securities downgraded shares of LivaNova from a “hold” rating to a “sell” rating and set a $50.00 price objective on the stock. in a research note on Tuesday, August 15th. Needham & Company LLC started coverage on shares of LivaNova in a research note on Wednesday, August 23rd. They issued a “hold” rating on the stock. Jefferies Group started coverage on shares of LivaNova in a research note on Friday, September 8th. They issued a “buy” rating and a $76.00 price objective on the stock. Piper Jaffray Companies restated an “overweight” rating and issued a $75.00 price objective on shares of LivaNova in a research note on Tuesday, September 12th. Finally, Canaccord Genuity restated a “hold” rating and issued a $71.00 price objective on shares of LivaNova in a research note on Wednesday, September 20th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $79.71.
In related news, Director Alfred J. Novak sold 2,000 shares of the firm’s stock in a transaction on Wednesday, November 22nd. The stock was sold at an average price of $85.77, for a total value of $171,540.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the firm’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $68.55, for a total value of $68,550.00. Following the completion of the transaction, the director now directly owns 57,296 shares of the company’s stock, valued at $3,927,640.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 6,830 shares of company stock valued at $557,100. 0.28% of the stock is owned by company insiders.
LivaNova PLC (NASDAQ:LIVN) opened at $82.62 on Monday. The company has a market capitalization of $3,980.00 and a price-to-earnings ratio of 23.81. LivaNova PLC has a 12-month low of $44.58 and a 12-month high of $88.56. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.03 and a quick ratio of 1.42.
LivaNova (NASDAQ:LIVN) last issued its earnings results on Thursday, November 2nd. The company reported $0.93 EPS for the quarter, topping the consensus estimate of $0.76 by $0.17. The firm had revenue of $309.70 million during the quarter, compared to analysts’ expectations of $301.22 million. LivaNova had a return on equity of 9.33% and a net margin of 4.63%. LivaNova’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period last year, the business earned $0.78 earnings per share. analysts predict that LivaNova PLC will post 3.33 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/11/stifel-financial-corp-has-10-97-million-holdings-in-livanova-plc-livn.html.
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related companies with MarketBeat.com's FREE daily email newsletter.